[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

(+1) 866-867-7178

Email address

clinicaltrials@novonordisk.com

Condition

Obesity,Overweight,Overweight,Overweight, Obesity and Diabetes Mellitus, Type 2,Overweight, Obesity and Diabetes Mellitus, Type 2,Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus

Treatment type

Interventional

Investigational product

Cagrilintide

Phase

Phase 3

Sponsor

Novo Nordisk A/S

ClinicalTrials.gov identifier

NCT05394519

Study number

NN9838-4609

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Male or female
  2. Age above or equal to 18 years at the time of signing informed consent
  3. BMI greather than or equal to 27.0 kg/m^2
  4. Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening
  5. Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose co-transporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulphonylureas (SU)s as a single agent or in combination) according to local label
  6. Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) for at least 90 days before screening
  7. HbA1c 7%-10% (53-86 mmol/mol) (both inclusive) as measured by the central laboratory at screening
Exclusion criteria

  1. Clinically significant or severe hypoglycaemia within 6 months before screening or history of hypoglycaemia unawareness
  2. Renal impairment with estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m^2, as measured by the central laboratory at screening
  3. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site